Bioequivalence of recombinant human FSH and recombinant human LH in a fixed 2:1 combination: Two phase I, randomised, crossover studies

Current Medical Research and Opinion

Volumn 24, Issue 4, 2008, Pages 1199-1208

  Picard, M ^a   Rossier, C ^a   Papasouliotis, O ^a   Lugan, Isabelle ^a  

^a Serono International SA   (Switzerland)

Author keywords

Bioequivalence; Combination, fixed; FSH; LH; Pharmacokinetics; Recombinant

Indexed keywords

FOLLITROPIN; GONADOTROPHIN RELEASING HORMONE AGONIST; LUTEINIZING HORMONE; PERGOVERIS; RECOMBINANT FOLLITROPIN; RECOMBINANT FOLLITROPIN PLUS RECOMBINANT LUTEINIZING HORMONE; RECOMBINANT LUTEINIZING HORMONE; UNCLASSIFIED DRUG;

ABDOMINAL DISTENSION; ABDOMINAL PAIN; ADULT; AREA UNDER THE CURVE; ARTICLE; BACKACHE; BIOEQUIVALENCE; CATHETER COMPLICATION; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; CROSSOVER PROCEDURE; DOWN REGULATION; DRUG FORMULATION; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEMALE; FLUSHING; HEADACHE; HOT FLUSH; HUMAN; INJECTION PAIN; MAJOR CLINICAL STUDY; MAXIMUM PLASMA CONCENTRATION; NAUSEA; NORMAL HUMAN; OUTCOME ASSESSMENT; RANDOMIZED CONTROLLED TRIAL; RASH; SIDE EFFECT; SORE THROAT; UPPER RESPIRATORY TRACT INFECTION;

ADOLESCENT; ADULT; AREA UNDER CURVE; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; FOLLICLE STIMULATING HORMONE, HUMAN; HUMANS; INJECTIONS, SUBCUTANEOUS; LUTEINIZING HORMONE; RECOMBINANT PROTEINS; THERAPEUTIC EQUIVALENCY;

EID: 42549113197     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079908X291949     Document Type: Article

References (22)

1. Burgues S. The effectiveness and safety of recombinant human LH to support follicular development induced by recombinant human FSH in WHO group I anovulation: Evidence from a multicentre study in Spain. Hum Reprod 2001;16:2525-32
2. The European Recombinant Human LH Study Group. Recombinant human luteinizing hormone (LH) to support recombinant human follicle-stimulating hormone (FSH)-induced follicular development in LH- and FSH-deficient anovulatory women: A dose-finding study. J Clin Endocrinol Metab 1998;83:1507-14
3. Stokman PG, de Leeuw R, van den Wijngaard HA, et al. Human chorionic gonadotropin in commercial human menopausal gonadotropin preparations. Fertil Steril 1993;60:175-8
4. van de Weijer BH, Mulders JW, Bos ES, et al. Compositional analyses of a human menopausal gonadotrophin preparation extracted from urine (menotropin). Identification of some of its major impurities. Reprod Biomed Online 2003;7:547-57
5. Driebergen R, Baer G. Quantification of follicle stimulating hormone (follitropin alfa): Is in vivo bioassay still relevant in the recombinant age? Curr Med Res Opin 2003;19:41-6
6. Bassett RM, Driebergen R. Continued improvements in the quality and consistency of follitropin alfa, recombinant human FSH. Reprod Biomed Online 2005;10:169-77
7. le Cotonnec JY, Porchet HC, Beltrami V, et al. Clinical pharmacology of recombinant human follicle-stimulating hormone (FSH). I. Comparative pharmacokinetics with urinary human FSH. Fertil Steril 1994;61:669-78
8. le Contonnec JY, Porchet HC, Beltrami V, et al. Clinical pharmacology of recombinant human follicle-stimulating hormone. II. Single doses and steady state pharmacokinetics. Fertil Steril 1994;61:679-86
9. Porchet HC, le Cotonnec JY, Loumaye E. Clinical pharmacology of recombinant human follicle-stimulating hormone. III. Pharmacokinetic- pharmacodynamic modeling after repeated subcutaneous administration. Fertil Steril 1994;61:687-95
10. le Cotonnec JY, Porchet HC, Beltrami V, Munafo A. Clinical pharmacology of recombinant human luteinizing hormone: Part II. Bioavailability of recombinant human luteinizing hormone assessed with an immunoassay and an in vitro bioassay. Fertil Steril 1998;69:195-200
11. le Cotonnec JY, Porchet HC, Beltrami V, Munafo A. Clinical pharmacology of recombinant human luteinizing hormone: Part I. Pharmacokinetics after intravenous administration to healthy female volunteers and comparison with urinary human luteinizing hormone. Fertil Steril 1998;69:189-94
12. le Cotonnec JY, Loumaye E, Porchet HC, et al. Pharmacokinetic and pharmacodynamic interactions between recombinant human luteinizing hormone and recombinant human follicle-stimulating hormone. Fertil Steril 1998;69:201-9
13. Lass A, McVeigh E. Routine use of r-hFSH follitropin alfa filled-by-mass for follicular development for IVF: A large multicentre observational study in the UK. Reprod Biomed Online 2004;9:604-10
14. Alviggi C, Mollo A, Clarizia R, De Placido G. Exploiting LH in ovarian stimulation. Reprod Biomed Online 2006;12:221-33
15. Caglar GS, Asimakopoulos B, Nikolettos N, et al. Recombinant LH in ovarian stimulation. Reprod Biomed Online 2005;10:774-85
16. Griesinger G, Diedrich K. Role of LH in ovarian stimulation: Considerations. Reprod Biomed Online 2006;12:404-6
17. Humaidan P. To add or not to add LH: Comments on a recent commentary. Reprod Biomed Online 2006;12:284-5
18. Meniru GI, Craft IL. Utilization of retrieved oocytes as an index of the efficiency of superovulation strategies for in-vitro fertilization treatment. Hum Reprod 1997;12:2129-32
19. Humaidan P, Bungum M, Bungum L, Yding Andersen C. Effects of recombinant LH supplementation in women undergoing assisted reproduction with GnRH agonist down-regulation and stimulation with recombinant FSH: An opening study. Reprod Biomed Online 2004;8:635-43
20. Marrs R, Meldrum D, Muasher S, et al. Randomized trial to compare the effect of recombinant human FSH (follitropin alfa) with or without recombinant human LH in women undergoing assisted reproduction treatment. Reprod Biomed Online 2004;8:175-82
21. Ferraretti AP, Gianaroli L, Magli MC, et al. Exogenous luteinizing hormone in controlled ovarian hyperstimulation for assisted reproduction techniques. Fertil Steril 2004;82:1521-6
22. De Placido G, Alviggi C, Perino A, et al. Recombinant human LH supplementation versus recombinant human FSH (rFSH) step-up protocol during controlled ovarian stimulation in normogonadotrophic women with initial inadequate ovarian response to rFSH. A multicentre, prospective, randomized controlled trial. Hum Reprod 2005;20:390-6